Cuenta de resultados
LARIMAR THERAPEUTICS, INC.
LRMR
Resumen del rendimiento
Haga clic en cualquier fila de la tabla para añadirla al gráfico
en millones de USD
| Métrica | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ingresos
|
- | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Coste de los ingresos
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Beneficio bruto
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Gastos operativos
|
172.50 | 90.89 | 41.76 | 36.53 | 50.47 | 42.80 | 45.65 | 61.12 | 53.00 | 58.23 | 73.81 | 35.53 |
|
Investigación y desarrollo
|
154.22 | 73.28 | 27.67 | 24.25 | 38.40 | 31.41 | 23.89 | 47.93 | 40.84 | 39.94 | 54.62 | 27.39 |
|
Ventas, generales y administrativos
|
18.27 | 17.61 | 14.09 | 12.28 | 12.07 | 11.40 | 16.22 | 13.19 | 12.16 | 18.29 | 19.20 | 8.14 |
|
Otros gastos operativos
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Resultado de explotación
|
-172.50 | -90.89 | -41.76 | -36.53 | -50.47 | -42.80 | -45.65 | -61.12 | -53.00 | -58.23 | -73.81 | -35.53 |
|
Ingresos no operativos
|
6.82 | 10.29 | 4.81 | 1.17 | -0.17 | 0.32 | 0.25 | -0.25 | 0.97 | 0.35 | -0.47 | -0.95 |
|
Ingresos por intereses
|
- | - | - | - | - | - | 1.99 | - | - | - | - | - |
|
Gastos por intereses
|
- | - | - | - | - | - | 1.77 | 1.90 | 0.17 | 0.53 | 0.81 | 0.87 |
|
Otros ingresos/gastos no operativos
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Resultado antes de impuestos
|
-165.67 | -80.60 | -36.95 | -35.36 | -50.64 | -42.48 | -45.41 | -61.37 | -52.03 | -57.88 | -74.29 | -36.48 |
|
Gasto por impuesto sobre beneficios
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Participaciones no dominantes
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Beneficio neto
|
-165.67 | -80.60 | -36.95 | -35.36 | -50.64 | -42.48 | -45.41 | -61.37 | -52.03 | -57.88 | -74.29 | -36.48 |
Información complementaria
Datos por acción, partidas derivadas y otras – no forman parte de la cuenta de resultados
en millones de USD, salvo que se indique lo contrario
| Métrica | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciación y amortización
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-172.50 | -90.89 | -41.76 | -36.53 | -50.47 | -42.80 | -45.65 | -61.12 | -53.00 | -58.23 | -73.81 | -35.53 |
|
Beneficio por acción (básico)
|
-1.19 | -1.32 | -0.84 | -1.37 | -2.95 | - | - | - | - | - | - | - |
|
BPA diluido
|
-1.19 | -1.32 | -0.84 | -1.37 | -2.95 | - | - | - | - | - | - | - |
|
Promedio ponderado de acciones
|
72.95 | 61.26 | 43.90 | 25.76 | 17.16 | - | - | - | - | - | - | - |
|
Promedio ponderado diluido de acciones
|
72.95 | 61.26 | 43.90 | 25.76 | 17.16 | - | - | - | - | - | - | - |
|
Resultado global
|
-165.77 | -80.54 | -36.84 | -35.39 | -50.64 | -42.48 | -45.34 | -61.34 | -52.01 | -57.75 | -74.46 | - |